Vaccine Technology Takes Center Stage In Rochester

October 08, 1998

Scientists from around the country are gathering in Rochester this weekend to review promising new vaccine technologies and discuss the status of vaccine efforts against HIV, other sexually transmitted diseases, ulcers and other maladies. The conference is being organized by the University of Rochester, where vaccine technology is at the centerpiece of a new research institute - and whose scientists created the vaccine that has nearly wiped out one form of childhood meningitis this decade.

More than 150 physicians, public health officials and research scientists will discuss everything from recent discoveries in biotechnology to efforts to assure that as many children and adults as possible receive the ever-growing battery of vaccines available. The meeting is Oct. 9-10 at the Crowne Plaza Hotel in downtown Rochester.

"It's a great time in vaccine research and development," says John Treanor, head of the University's Vaccine Evaluation Unit. "There have been a tremendous number of advances in molecular biology and in our understanding of the human immune response. We're now seeing those basic science advances spur an explosion of progress in vaccine development."

The meeting will include presentations on new vaccine technology, updates on immunization efforts against HIV, Lyme disease, Helicobacter (the bacterium that causes most stomach ulcers), and discussions on immunization strategies. Speakers include Claire Broome, acting director of the Centers for Disease Control and Prevention; John LaMontagne, deputy director of the National Institute of Allergy and Infectious Diseases; Tim Mosmann, director of the University's new Center for Vaccine Biology and Immunology; and George Siber, chief scientific officer at Wyeth-Ayerst Pharmaceuticals, the firm that manufactures the meningitis vaccine and others.

"Preventing disease and saving lives through immunization is a top priority of governments and physicians worldwide," says Barbara Iglewski, professor and chair of the Department of Microbiology and Immunology and an organizer of the conference.

"The spotlight in biotechnology really is shining on vaccines, making this an opportune time for a vigorous research effort, such as the new Center for Vaccine Biology and Immunology."

At the vanguard of the renaissance in vaccine research was the creation by University scientists of a vaccine against Haemophilus influenzae b (Hib), a microbe that causes bacterial meningitis and other diseases. The bacterium used to infect about 20,000 children in the United States alone each year, killing more than 1,000 and leaving thousands of youngsters deaf, blind, paralyzed, or with mental retardation. Since approval of the vaccine by the Food and Drug Administration in 1990, the number of children infected has been reduced by about 98 percent - only a few hundred children each year get sick from the microbe. The vaccine is now made and sold by Wyeth-Ayerst, a division of American Home Products.

As important as the vaccine itself is the underlying technology developed by former professors David Smith and Porter Anderson and current faculty member Richard Insel. In the early 1980s, many large companies had turned away from vaccine research for a host of reasons, but Smith felt the work was so promising that he left the University and founded his own firm, Praxis Biologics Inc., to commercialize the vaccine. The vaccine became the first in 20 years to be recommended by the Food and Drug Administration for universal use in all children. Smith poured many of the profits back into research, and scientists were able to use the same technology to create a promising vaccine against the pneumococcus bacterium, the leading cause of ear infections and the remaining cases of meningitis in children. At the conference, scientists from Wyeth Lederle Vaccines, which produces the vaccine, will discuss results of recent tests.

Now vaccine research around the country is booming, and Rochester residents are among the first to benefit from new developments, because the University is one of five sites designated by the National Institutes of Health to evaluate new vaccines. Thus the research community relies on physicians from the University and the Rochester community - and their patients - to evaluate new vaccines. "Most of these studies are only possible because pediatricians in town are so cooperative and supportive. It's a tribute to this community," says Treanor.

Among the current vaccine-related research at the University:
Rochester has become a national model not only in such research but also in ensuring that as many people as possible are immunized. Physician Peter Szilagyi created a program that has boosted the numbers of children in inner-city Rochester receiving vaccines by about 20 percent. Szilagyi worked closely with public health officials to create an extensive reminder and outreach program to overcome barriers such as lack of transportation, poor record-keeping by parents and doctors, and lack of communication that has resulted in nearly half of children going without necessary immunizations. "You can make the best vaccines in the world, but if you can't get them to the people who need them, they're worthless," says Szilagyi.
-end-


University of Rochester

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.